Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 10/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177601 | 0.87 | CHEK2 (0.66) | CHEK2ALDH1A1PRMT1 | |
| SCHEMBL1384653 | 0.86 | CHEK2 (0.65) | CHEK2ALDH1A1PRMT1 | |
| SCHEMBL5178049 | 0.85 | CHEK2 (0.67) | CHEK2ALDH1A1LMNATSHRHTT | |
| SCHEMBL5176583 | 0.84 | CHEK2 (0.68) | CHEK2GAA | |
| SCHEMBL5177233 | 0.82 | CHEK2 (0.68) | CHEK2POLBALDH1A1LMNAHTT | |
| SCHEMBL5177628 | 0.82 | CHEK2 (0.72) | CHEK2ALDH1A1TSHR | |
| SCHEMBL5177810 | 0.82 | CHEK2 (0.67) | CHEK2ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL5178080 | 0.82 | CHEK2 (0.67) | CHEK2POLB | |
| SCHEMBL5177744 | 0.82 | CHEK2 (0.69) | CHEK2POLBALDH1A1 | |
| SCHEMBL5178184 | 0.81 | CHEK2 (0.68) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613313-B1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5]-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | EP | claimed |